PSTVBack in Nasdaq’s good graces
Plus Therapeutics just got the kind of email every tiny public company wants to see: Nasdaq says PSTV is back in compliance with the exchange’s minimum bid price rule. Translation: the stock managed to stay at or above $1.00 for 10 consecutive business days, from April 6 through April 17.
Why this matters
This isn’t the sexy kind of biotech headline where a drug suddenly looks like the next blockbuster. It’s more of a “please stop worrying about the fire alarm” update. For investors, regaining compliance removes an overhang that can scare off traders, institutions, and anyone who hates uncertainty more than they hate red ink.
The boring stuff that can still move a stock
When a microcap gets too close to penny-stock territory, the market starts acting like it heard a suspicious noise in the basement. Getting back above the line can help stabilize sentiment, even if it doesn’t change the company’s science, cash runway, or commercialization prospects one bit.
Big picture
For Plus Therapeutics, this is less about victory lap and more about escaping penalty box status. The company still has to prove the actual business, but at least for now, Nasdaq isn’t hovering over its shoulder with a rulebook and a flashlight.